Insiders · CARA

CARA insider transactions

Cara Therapeutics Inc. (CARA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for CARA

• 413d
  SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by VP, Chem, Mfg and Ctrls Chen Yixin

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Shiff Susan Ph.D.

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Smith Cynthia

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Wirk Shaheen

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Shah Sujal

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Wyzga Michael S

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 413d
  SEC Form 4 filed by Director Hall Wallace L Jr

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  Director Hall Wallace L Jr acquired 246,756 shares (SEC Form 4)

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Director Wyzga Michael S

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  Director Wirk Shaheen was granted 4,191 shares and acquired 439,194 shares (SEC Form 4)

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Director Shah Sujal

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by VP, Chem, Mfg and Ctrls Chen Yixin

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

  4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider O'Brien Stephen Paul

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Wyzga Michael S

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Hall Wallace L Jr

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Wirk Shaheen

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Conn Avi Daniel

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Shah Sujal

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Kauh John Saewook M.D.

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Alibhai Imran Nizamudin

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Smith Cynthia

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Chen Yixin

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 417d
  SEC Form 3 filed by new insider Larson Jeffrey Leroy

  3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
• 461d
  PRESIDENT AND CEO Posner Christopher sold $2,769 worth of shares (583 units at $4.75), decreasing direct ownership by 4% to 13,109 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 461d
  SEC'Y; CHIEF COMPLIANCE & G.C. Terrillion Scott sold $776 worth of shares (163 units at $4.76), decreasing direct ownership by 2% to 7,190 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 487d
  PRESIDENT AND CEO Posner Christopher sold $1,756 worth of shares (372 units at $4.72), decreasing direct ownership by 3% to 13,692 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 579d
  PRESIDENT AND CEO Posner Christopher sold $1,064 worth of shares (3,668 units at $0.29), decreasing direct ownership by 2% to 168,768 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 675d
  PRESIDENT AND CEO Posner Christopher sold $1,452 worth of shares (4,149 units at $0.35), decreasing direct ownership by 2% to 172,436 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 732d
  Boudreau Helen M was granted 150,647 shares (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 732d
  Von Moltke Lisa was granted 150,647 shares, increasing direct ownership by 466% to 183,009 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 732d
  Ives Jeffrey L. was granted 150,647 shares, increasing direct ownership by 315% to 198,485 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 732d
  Shiff Susan Ph.D. was granted 150,647 shares, increasing direct ownership by 293% to 202,085 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 732d
  Vogelbaum Martin was granted 301,295 shares, increasing direct ownership by 275% to 411,007 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 763d
  Posner Christopher sold $2,952 worth of shares (3,936 units at $0.75), decreasing direct ownership by 2% to 176,585 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 790d
  Goncalves Joana sold $2,285 worth of shares (2,753 units at $0.83), decreasing direct ownership by 5% to 53,365 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 790d
  Terrillion Scott sold $2,285 worth of shares (2,753 units at $0.83), decreasing direct ownership by 3% to 88,247 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 826d
  Terrillion Scott sold $2,931 worth of shares (3,293 units at $0.89), decreasing direct ownership by 3% to 91,000 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 826d
  Posner Christopher sold $5,192 worth of shares (5,834 units at $0.89), decreasing direct ownership by 3% to 180,521 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 826d
  Goncalves Joana sold $2,931 worth of shares (3,293 units at $0.89), decreasing direct ownership by 6% to 56,118 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 847d
  Terrillion Scott sold $4,118 worth of shares (7,770 units at $0.53), decreasing direct ownership by 8% to 94,293 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 847d
  Maynard Ryan D sold $2,909 worth of shares (5,488 units at $0.53), decreasing direct ownership by 41% to 8,012 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 847d
  Goncalves Joana sold $4,118 worth of shares (7,770 units at $0.53), decreasing direct ownership by 12% to 59,411 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 847d
  Posner Christopher sold $18,855 worth of shares (35,575 units at $0.53), decreasing direct ownership by 16% to 186,355 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 854d
  Terrillion Scott was granted 13,500 shares, increasing direct ownership by 15% to 102,063 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 854d
  Maynard Ryan D was granted 13,500 shares (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 854d
  Goncalves Joana was granted 13,500 shares, increasing direct ownership by 25% to 67,181 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 854d
  Menzaghi Frederique Ph.D. was granted 13,500 shares, increasing direct ownership by 9% to 167,247 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 854d
  Posner Christopher was granted 62,500 shares and sold $2,740 worth of shares (4,981 units at $0.55), increasing direct ownership by 35% to 221,930 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 948d
  Posner Christopher sold $4,631 worth of shares (3,796 units at $1.22), decreasing direct ownership by 2% to 164,411 units (SEC Form 4)

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
• 1039d
  SEC Form 4: Posner Christopher sold $13,222 worth of shares (4,307 units at $3.07), decreasing direct ownership by 2% to 168,207 units

  4 - Cara Therapeutics, Inc. (0001346830) (Issuer)